부산대학교 도서관

Clinical studies on Azthreonam (SQ 26, 776), a new monobactam antibiotic, having activity against Gram-negative bacilli and cocci, developed by the Squibb & Sons incorporated, were performed, and the results were as follows:A total of 11 patients with various infections, having underlying diseases were treated with this drug, 1-2g twice daily for 5-13 days by intravenous drip infusion.Five out of 10 cases evaluated responded satisfactorily to the treatment and efficacy rate was 50%.According to the bacteriological study, one strain of Klebsiella pneumoniae, 2 of Pseudomonas aeruginosa, 2 of Haemophilus influenzae and 1 of Proteus mirabilis were eliminated. Five out of 6 strains of Escherichia coli were also eradicated and a remainder was reduced in number after Azthreonam treatment. Two strains of Streptococcus faecalis appeared to be isolated from the urine of patients with urinary tract infection after Azthreonam treatment.One case with biliary tract infection, having underlying disease of cholangioma had an abnormal elevation of S-GOT, S-GPT and alkaline phosphatase after treatment, however, these findings were considered to be due to malignant disease.Azthreonam seems to be very useful in treatment of Gram-negative bacilli infections.